lung cancer

FDA Grants Regular Approval to Dabrafenib and Trametinib Combination for Metastatic NSCLC With BRAF V600E Mutation

On June 22, 2017, the U.S. Food and Drug Administration granted regular approvals to dabrafenib (Tafinlar) and trametinib (Mekinist) administered in combination for patients with metastatic non–small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These ...

palliative care

Impact of Palliative Care on End-of-Life Services for Patients Dying in a Hospital

In a single-center retrospective analysis reported in the Journal of Oncology Practice, Wiesenthal et al found that among patients dying in a hospital, those with palliative care in place at final admission received less diagnostic testing and other services not associated with promoting patient...

lung cancer

Atezolizumab as First-Line or Subsequent Treatment in PD-L1–Selected Advanced NSCLC

In the phase II BIRCH trial, atezolizumab (Tecentriq) was found to produce higher response rates as first-line or subsequent therapy in patients with advanced non–small cell lung cancer (NSCLC) with higher levels of programmed cell death ligand 1 (PD-L1) expression. Study findings were...

leukemia
lymphoma

FDA Approves Rituximab Plus Hyaluronidase Combination for Treatment of Certain Hematologic Malignancies

On June 22, 2017, the U.S. Food and Drug Administration granted regular approval to the combination of rituximab and hyaluronidase human (Rituxan Hycela) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. The approval provides a...

leukemia

Phase III CASCADE Trial of Front-Line Vadastuximab Talirine in AML Discontinued

Seattle Genetics has discontinued its phase III CASCADE clinical trial of front-line vadastuximab talirine (SGN-CD33A) in older acute myeloid leukemia (AML) patients. The phase III CASCADE clinical trial is a randomized, double-blind, placebo-controlled study evaluating vadastuximab talirine...

breast cancer

NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer

According to Surveillance, Epidemiology, and End Results (SEER) data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the National Comprehensive Cancer Network®...

issues in oncology

Canadian Cancer Society Report: Nearly 1 in 2 Canadians Expected to Be Diagnosed With Cancer in Their Lifetime

Nearly 1 in 2 Canadians is expected to be diagnosed with cancer in their lifetime, according to a new report—Canadian Cancer Statistics 2017—released by the Canadian Cancer Society (CCS) in partnership with the Public Health Agency of Canada and Statistics Canada. For males, the...

issues in oncology

Digital Technology Preferences of Adolescents and Young Adults With Cancer

There is considerable scope to develop digital resources by means of which teenagers and young adults living with cancer can receive information and connect with both professionals and fellow patients. Such tools could help them gain different perspectives on treatment and survivorship, said Esha...

pancreatic cancer

WCHN Launches Trial to Screen Newly Diagnosed Patients With Diabetes for Early-Stage Pancreatic Cancer

Western Connecticut Health Network (WCHN) has announced the launch of a 3-year research study that will investigate the link between new-onset diabetes and pancreatic cancer. The main goal is to detect the often lethal cancer at a curable stage. The study was developed by a team of physicians and...

colorectal cancer

Effect of Postdiagnosis Aspirin and Other NSAIDs on Survival in Colorectal Cancer

As reported by Hua et al in the Journal of Clinical Oncology, long-term survivors of colorectal cancer with KRAS wild-type tumors had improved survival with regular use of any nonsteroidal anti-inflammatory drug (NSAID) post diagnosis. The study involved data from 2,149 patients aged 18 to 74...

breast cancer

Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Adjuvant Therapy for Breast Cancer

The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by...

lymphoma

ICML 2017: 3-Year Follow-up Showed Fourfold Progression-Free Survival Benefit With Ibrutinib vs Temsirolimus at First Relapse in Mantle Cell Lymphoma

Three-year follow-up data from the phase III RAY study in patients with relapsed or refractory mantle cell lymphoma were presented at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. These results demonstrated that the subset of patients treated with ibrutinib...

lymphoma

ICML 2017: Data From the TRANSCEND Trial of JCAR017 in Relapsed and Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B-cell non-Hodgkin lymphoma (NHL) was presented at the 2017 International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. JCAR017 is Juno Therapeutics’ investigative chimeric antigen receptor (CAR) ...

lymphoma

ICML 2017: Phase IIIb MAGNIFY Study of Lenalidomide and Rituximab Combination in Relapsed/Refractory Follicular and Marginal Zone Lymphoma

An interim analysis of MAGNIFY, a phase IIIb, randomized, open-label, multicenter study of the R2 combination regimen (lenalidomide [Revlimid] plus rituximab [Rituxan]) in patients with relapsed or refractory marginal zone lymphoma, was presented at the International Conference on Malignant...

lymphoma

ICML 2017: Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma

An updated interim analysis from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma was presented at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (Abstract...

lymphoma

ICML 2017: ADCT-402 Demonstrates Encouraging Antitumor Activity in Relapsed/Refractory Non-Hodgkin Lymphoma

Clinical data from an ongoing phase I clinical trial evaluating ADCT-402 for the treatment of relapsed or refractory non-Hodgkin lymphoma was presented at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. ADCT-402 is a novel antibody-drug conjugate composed of a ...

breast cancer

Equivalence Trial of Neoadjuvant Trastuzumab Biosimilar CT-P6 vs Trastuzumab in HER2-Positive Breast Cancer

A phase III equivalence trial has shown comparable pathologic complete response rates with the proposed trastuzumab biosimilar CT-P6 vs reference trastuzumab (Herceptin) in neoadjuvant treatment of HER2-positive early breast cancer. The study was reported by Stebbing et al in The Lancet Oncology....

cns cancers

FDA Approves Aminolevulinic Acid Hydrochloride as an Optical Imaging Agent Indicated in Gliomas

On June 6, the U.S. Food and Drug Administration (FDA) approved aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan), as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization [WHO] Grades III or IV) for preoperative imaging, as an adjunct for the...

leukemia

ICML 2017: Phase III GENUINE Trial: Ublituximab Plus Ibrutinib in High-Risk CLL

Data was recently presented from the phase III GENUINE trial of ublituximab, a novel glycoengineered anti–CD20 monoclonal antibody, in combination with ibrutinib (Imbruvica), a Bruton tyrosine kinase (BTK) inhibitor, for the treatment of high-risk chronic lymphocytic leukemia (CLL), at the...

leukemia
lymphoma

ICML 2017: Triplet Combination of Umbralisib, Ublituximab, and Ibrutinib in CLL/SLL/NHL

Data from the chemotherapy-free triple combination of umbralisib, an oral, next generation PI3K delta inhibitor; ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody; and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and...

lymphoma

ICML 2017: Phase II Trial of Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL

Positive interim efficacy data from an ongoing phase II clinical trial of tazemetostat, a first-in-class, oral enhancer of zeste homolog 2 (EZH2) inhibitor, as a single-agent treatment for relapsed or refractory patients with follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) grouped by...

palliative care

Effect of Embedding Palliative Care in an Oncology Clinic

A retrospective analysis reported in the Journal of Oncology Practice by Einstein et al showed the benefits of embedding palliative care in a clinic specializing in targeted and immune-based treatments in patients with melanoma or renal cancer. Study Details The study included data from 114...

breast cancer

Trends in Surgery After Initial Lumpectomy for Breast Cancer

In a study reported in JAMA Oncology, Morrow et al found that the rates of surgery after initial lumpectomy for stage I or II breast cancer have decreased with dissemination of guidelines advocating a minimal negative surgical margin. A 2014 consensus statement of the Society of Surgical Oncology...

prostate cancer

SNMMI 2017: Preclinical Targeted Photodynamic Therapy Shown Highly Effective Against Prostate Cancer

Researchers presented a preclinical study at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) that demonstrated the efficacy and optimal dose for targeted photodynamic therapy (PDT) to treat prostate cancer before and during surgery (Abstract 7). Targeted...

solid tumors

SNMMI 2017: Combining PRRT With a PARP Inhibitor May Slow Neuroendocrine Tumor Growth

Patients with neuroendocrine tumors may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more sensitive to radiation therapy, said researchers at the 2017 Annual Meeting of the Society of Nuclear...

breast cancer
prostate cancer

SNMMI 2017: Imaging Metastatic Breast and Prostate Cancer Using Dual-Agent PET/MRI With Time of Flight

Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (F-18 FDG) and fluorine-18 sodium fluoride (F-18 NaF) followed by quantitative scanning significantly improved image quality and detection of bone metastases at a lower dose, according to research presented at...

multiple myeloma
cost of care

Impact of Subsidies on Use of Oral Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

According to a study by Olszewski and colleagues in the Journal of Clinical Oncology, Medicare Part D beneficiaries without a low-income subsidy may face daunting barriers in affording oral immunomodulatory drugs for myeloma. The low-income subsidy markedly reduces out-of-pocket costs for...

lung cancer

Ceritinib vs Chemotherapy in Previously Treated ALK-Rearranged NSCLC

The phase III ASCEND-5 trial has shown a significant improvement in progression-free survival with ceritinib (Zykadia) vs chemotherapy in advanced ALK-rearranged non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori) and chemotherapy. Trial results were reported in...

multiple myeloma

FDA Approves Daratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has approved the use of daratumumab (Darzalex) in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid) and a...

solid tumors
pancreatic cancer

SNMMI 2017: Immuno-PET Shows Promise for Detecting and Treating Pancreatic Tumors, Other Solid Tumors

A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Abstract 385) demonstrated the feasibility and safety of imaging with the novel human monoclonal antibody HuMab-5B1, to enable highly specific targeting for the cancer...

SNMMI 2017: Personalized PRRT Improves Radiation Delivery to Neuroendocrine Tumors

Neuroendocrine tumors are difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient doses of peptide receptor radionuclide therapy (PRRT), according to research presented at the 2017 Annual Meeting of the...

prostate cancer

SNMMI 2017: PET/CT, Clinical Management, and Disease Detection in Prostate Cancer

An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific molecular imaging can help to clinically manage the disease much more efficiently, especially if the cancer returns, according to research revealed at the 2017 Annual Meeting of the...

gastroesophageal cancer

High-Dose First-Line Trastuzumab Maintenance in Metastatic HER2-Positive Gastric Cancer

As reported in the Journal of Clinical Oncology by Shah et al, the phase IIIB HELOISE trial has shown no survival benefit of high-dose vs standard trastuzumab (Herceptin) maintenance plus chemotherapy in the first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma....

issues in oncology

CancerCare Establishes Patient Values Initiative, Releases Focus Group Assessment

CancerCarehas announced the establishment of the CancerCare Patient Values Initiative, a multipronged effort with an aim to reframe the national health-care policy dialogue so that it includes what is important to patients and their families. As the first step of this important project,...

lung cancer

ASTRO Issues Guideline for Use of Stereotactic Radiation in Early-Stage Lung Cancer

The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer. While SBRT is the current standard of care for peripherally located tumors in patients who cannot undergo surgery, the new...

gynecologic cancer

Dutch Study Assesses Long-Term Risk of HPV-Related Carcinoma and Premalignancies After CIN3 Diagnosis

A Dutch study has shown long-lasting risk for human papillomavirus (HPV)-related carcinoma and premalignancies in women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3). The findings were reported by Ebisch et al in the Journal of Clinical Oncology. Study Details The...

breast cancer

Combination of Buparlisib and Fulvestrant in Postmenopausal Women With Advanced Breast Cancer

In the phase III BELLE-2 trial, the addition of the PI3K inhibitor buparlisib to fulvestrant (Faslodex) improved progression-free survival in postmenopausal hormone receptor–positive, HER2-negative advanced breast cancer—but at the cost of excessive toxicity. Results were reported in...

solid tumors
head and neck cancer

PD-L2 Expression and Clinical Response to Pembrolizumab in Head and Neck Cancer

A study assessing the prevalence and distribution of programmed cell death ligand 2 (PD-L2) in human tumor samples across seven cancer indications, including renal cell carcinoma, bladder, melanoma, non–small cell lung cancer, triple-negative breast cancer, gastric carcinoma, and head and...

Vital Options International Introduces Free eBook, The Cancer Concierge

Between the onslaught of bills and the endless stream of tests and appointments, managing cancer treatment can be overwhelming.  There needs to be a good organizing system in place from the very first oncologist appointment. No one understood this better than the Founder of Vital Options ...

AACR Publishes First Set of Screening Recommendations Emerging From Childhood Cancer Predisposition Workshop

The American Association for Cancer Research (AACR) has published its first set of consensus screening recommendations for children with common cancer predisposition syndromes in Clinical Cancer Research. These recommendations emerged from the Childhood Cancer Predisposition Workshop held by the...

solid tumors

Pembrolizumab in Solid Tumors With Mismatch-Repair Deficiency

As reported by Le et al in Science, pembrolizumab (Keytruda) was found to be active across a range of solid tumors with mismatch-repair (MMR) deficiency. Pembrolizumab was recently approved for treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or...

gastroesophageal cancer

Association of EGFR Copy Number Gain and Outcome With Gefitinib in Advanced Esophageal Cancer

As reported by Petty et al in the Journal of Clinical Oncology, analysis of outcomes in the UK phase III Cancer Esophagus Gefitinib trial showed an overall survival benefit with second-line gefitinib (Iressa) in patients with advanced esophageal cancer who had epidermal growth factor receptor...

breast cancer

Adding Abemaciclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

In the phase III MONARCH 2 trial reported at the recent ASCO Annual Meeting and in the Journal of Clinical Oncology by Sledge et al, the addition of the selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib to fulvestrant (Faslodex) improved progression-free survival in hormone...

Oncologist Barbara L. McAneny, MD, Elected AMA President-Elect

Physicians gathering at the Annual Meeting of the American Medical Association (AMA) elected Barbara L. McAneny, MD, an oncologist from Albuquerque, New Mexico, as the new President-Elect of the nation’s premier physician organization. Following a year-long term as President-Elect, Dr....

First Analysis of AACR Project GENIE Data Published

The first analysis of nearly 19,000 de-identified genomic records from the American Association for Cancer Research (AACR) international data-sharing initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) was recently published in Cancer Discovery. In addition to ...

health-care policy

ASCO 2017: SWOG Clinical Trials Have Added More Than 3 Million Years of Life for Patients With Cancer

For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute (NCI)-funded SWOG clinical trials program has added 3.34 million years of life for patients with cancer in the United States because of successful therapies that were proved through its trials....

lung cancer

Sacituzumab Govitecan in Previously Treated Patients With Metastatic NSCLC

As reported by Heist et al in the Journal of Clinical Oncology, the antibody-drug conjugate sacituzumab govitecan showed activity in patients with previously treated metastatic non–small cell lung cancer (NSCLC). Sacituzumab targets Trop-2, present on many solid tumors; govitecan is the...

skin cancer

Melanoma-Specific Survival With Completion Dissection vs Observation for Sentinel Node Metastasis

The phase III MSLT-II trial showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel node metastasis, although a benefit was observed in regional disease control. The findings were reported in The New England...

breast cancer

ASCO 2017: I-SPY 2 Trial: Combination of Pembrolizumab Plus Standard Neoadjuvant Therapy in High-Risk Breast Cancer

At the 2017 ASCO Annual Meeting, results were presented from the phase II I-SPY 2 trial investigating pembrolizumab (Keytruda) in combination with standard therapy (paclitaxel followed by doxorubicin and cyclophosphamide) as a neoadjuvant treatment for patients with locally advanced triple-negative ...

pain management

FDA Requests Removal of Oxymorphone Hydrochloride for Risks Related to Abuse

On June 8,the U.S. Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated oxymorphone hydrochloride (Opana ER), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the...

Advertisement

Advertisement



Advertisement

click me